Yesterday, I articulated our strategy for protecting remaining beta cells and brain cells with MANF.
1. Inject recombinant MANF to patients.
2. Stabilize endogenous MANF
3. Activate a receptor for MANF
I feel that these are realistic plans. The same strategy has been applied to GLP-1, a molecule produced in our guts, and GLP-1 related drugs are widely and successfully used for patients with type 2 diabetes.
We are currently focusing on "recombinant" MANF, and hope to expand our research in this area.